Home Featured Page 232

Featured

Latest

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.

When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference

Weekly Psychedelic Policy Briefing: September 30th, 2026

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to...

PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye...

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

MINDCURE Provides Update on Studies and Clinical Trials

Cybin Granted DEA Schedule I Manufacturing License

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

EDITOR PICKS

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA...

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.

When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference

Weekly Psychedelic Policy Briefing: September 30th, 2026

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to...

PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye...

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

MINDCURE Provides Update on Studies and Clinical Trials

Cybin Granted DEA Schedule I Manufacturing License

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion...

EDITOR PICKS

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA...

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY